SPY003

Phase 2Small molecule

SSpyre Therapeutics, Inc.

SPY003 is one of 40 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisActive, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

460 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Velsipity

Pfizer

Phase 3

11 2

Jyseleca

Gilead

Phase 3

6 3

Skyrizi

AbbVie

Phase 3

6 4

Tremfya

Johnson & Johnson

Phase 3

2 5

Mounjaro

Eli Lilly

Phase 3

1 6

Orencia

Bristol-Myers Squibb

Phase 3

1 7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Adtralza

LEO Pharma

Phase 3

1 9

Purinethol

SStason

Phase 3

1 10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Ulcerative Colitis

NCT07012395

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis

Recruiting·SSpyre Therapeutics, Inc.·Phase 2·NCT07012395·645 enrolled

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants With Inflammatory Bowel Disease

Enrolling by invitation·SSpyre Therapeutics, Inc.·Phase 2·NCT07652294·645 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for SPY003. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPY003 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPY003. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Spyre Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSpyre Therapeutics, Inc.

SPY003

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Ulcerative Colitis2 trials

References

Drug Info

Quick Facts

Related News